GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
147.47
+4.24 (+2.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close143.23
Open147.35
Bid143.00 x 1000
Ask149.99 x 1200
Day's Range143.89 - 149.61
52 Week Range101.07 - 179.65
Volume552,907
Avg. Volume507,695
Market Cap4.77B
Beta (3Y Monthly)2.89
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.33
Trade prices are not sourced from all markets
  • Marijuana stocks to watch: Meet the drugmaker making cannabis-based medicines for autism, cancer and more
    MarketWatch45 minutes ago

    Marijuana stocks to watch: Meet the drugmaker making cannabis-based medicines for autism, cancer and more

    Drugmakers commonly make their medicines synthetically — think a lab, not a greenhouse. But because its medications employ cannabinoids, the U.K.-based GW Pharma also grows it own cannabis plants.

  • Investopedia16 hours ago

    The Most Unique Pot Stocks

    Canada has set October 17, 2018, as the date that adults in the country will be legally able to purchase cannabis for recreational use through licensed dispensaries and, in some areas, online. Canada has already taken an early lead when it comes to the legal cannabis industry, with many U.S. states moving to follow its path toward legalization. With the legal marijuana industry growing at a rapid pace, many analysts see the next stage of growth as one of differentiation.

  • Marijuana Stocks to Watch in October -- and Into 2019
    Motley Fool21 hours ago

    Marijuana Stocks to Watch in October -- and Into 2019

    Looking for a marijuana stocks list with key data included? Look no further.

  • 5 Marijuana Stocks to Watch
    InvestorPlace2 days ago

    5 Marijuana Stocks to Watch

    To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Initial products such as Epidiolex and Sativex are used to treat epilepsy and spasticity caused by multiple sclerosis.

  • ACCESSWIRE2 days ago

    Why This Company is Set for a Major Breakout

    HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...

  • 5 of the Most Unique Marijuana Stocks
    Motley Fool2 days ago

    5 of the Most Unique Marijuana Stocks

    These pot stocks stand out in a very crowded field.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...

  • How to Invest in Marijuana Stocks
    Motley Fool5 days ago

    How to Invest in Marijuana Stocks

    Seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

  • Investopedia6 days ago

    How GW Pharmaceuticals is Changing the Cannabis Game in the U.S.

    One of the hottest areas in the investment world today is legal cannabis. Although marijuana and related products are not fully legal across the United States, the move by individual states to legalize cannabis for medical or, in some cases, recreational use has opened up many avenues for potential investment opportunities. GW Pharmaceuticals PLC ADR ( GWPH) is a biopharmaceutical company headquartered in the U.K. GW aims to develop products within the medical cannabis portion of the legal marijuana industry.

  • ACCESSWIRE7 days ago

    Top Beverage Companies Entering CBD

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...

  • Marijuana ETFs: How to Find the Best Exchange-Traded Funds
    Motley Fool8 days ago

    Marijuana ETFs: How to Find the Best Exchange-Traded Funds

    If you're interested in profiting from the marijuana movement, you might want to consider owning a marijuana exchange-traded fund.

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool10 days ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Despite getting lumped in with riskier marijuana stocks, these two biotechs are worth a closer look.

  • Why GW Pharmaceuticals Stock Jumped 17.7% in September
    Motley Fool11 days ago

    Why GW Pharmaceuticals Stock Jumped 17.7% in September

    This marijuana stock had a good month last month thanks to a regulatory first. Here's what investors should know.

  • Benzinga12 days ago

    Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

    In market-related news, shares of Tilray Inc (NASDAQ: TLRY) tumbled Tuesday, after beverage giant PepsiCo, Inc. (NASDAQ: PEP) put an end to speculation about a potential entry into the cannabis space. “I think the difficulties in investing in that category, particularly in the U.S., where federally these things are still not legal, are quite a considerable challenge,” PepsiCo Chief Financial Officer Hugh Johnston said on a company call. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) said it was issuing 1.9 million ADSs in a bid to raise $300 million.

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist12 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • New Age Beverages Stock Bubbles Higher on Upcoming CBD Drinks Launch
    InvestorPlace12 days ago

    New Age Beverages Stock Bubbles Higher on Upcoming CBD Drinks Launch

    According to New Age Beverages (NASDAQ:NBEV) CEO Brent Willis, the company is preparing to show off its new line of CBD drinks next week. While that’s good news for New Age Beverages stock, it isn’t the major launch that some investors may be hoping for. Instead, the company is still talking to retailers about selling the drinks in states where they are legal.

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist12 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Marijuana-Focused Biotech Companies in Q3: Are They Performing?
    Market Realist12 days ago

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.

  • ACCESSWIRE12 days ago

    Cannabis Industry Service Provider Solving Major Challenges

    HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...

  • GlobeNewswire12 days ago

    GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).

  • Benzinga14 days ago

    The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Boston Scientific Corporation (NYSE: BSX ) Eli Lilly ...

  • GlobeNewswire14 days ago

    GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.

  • Investor's Business Daily15 days ago

    Dow Jones Futures: Hot IPO Stitch Fix Dives, Marijuana Stocks India Global, New Age Beverages Swing Wildly

    Stock futures: Hot IPO Stitch Fix earnings topped, but other metrics missed. Stitch Fix stock dived. Marijuana plays New Age Beverages, India Globalization and DavidsTea were volatile.

  • ACCESSWIRE15 days ago

    DEA Rescheduling Makes CBD Stocks Blazing Hot

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.

  • Benzinga15 days ago

    The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...